Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,504.47 86.94 0.60%
TOPIX 1,170.04 3.45 0.30%
HANG SENG 22,760.24 64.23 0.28%

AbbVie Files Form 10-K; Calls Annual Meeting of Stockholders

PR Newswire/Les Echos/

AbbVie Files Form 10-K; Calls Annual Meeting of Stockholders

NORTH CHICAGO, Ill., March 18, 2013 -- AbbVie Inc. ("AbbVie") (NYSE / CHX / Euronext Paris / SIX: ABBV) informs its stockholders that it has filed its Annual Report on Form 10-K with the U.S. Securities and Exchange Commission ("SEC").

AbbVie also informs its stockholders that the Annual Meeting of Stockholders will be held at the Beechwood Hotel, 363 Plantation Street, Worcester, Massachusetts 01605, on Monday, May 6, 2013, at 9:00 a.m. for the following purposes:

* To elect three directors to hold office until the next Annual Meeting or

until their successors are elected, * To ratify the appointment of Ernst & Young LLP as auditors of AbbVie for

2013, * To vote on an advisory vote on the approval of executive compensation, * To determine, in an advisory vote, whether the stockholder advisory vote

to approve executive compensation should occur every one, two or three

years, * To approve the AbbVie 2013 Incentive Stock Program, and * To transact such other business as may properly come before the meeting.

The close of business on March 8, 2013, has been fixed as the record date for determining the stockholders entitled to receive notice of and to vote at the Annual Meeting.

AbbVie makes available free of charge on its website, its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, reports filed pursuant to Section 16 of the U.S. Securities Exchange Act of 1934 and amendments to those reports filed with or furnished to the SEC as soon as reasonably practicable after AbbVie electronically files these documents with, or furnishes them to, the SEC. These documents are posted on AbbVie's website at

The SEC maintains a website that contains reports, proxy statements and other information regarding issuers that file electronically with the SEC. These materials may be obtained electronically by accessing the SEC's home page at

Copies of the above referenced information will also be made available, free of charge, upon written request to AbbVie Inc., Investors Relations, 1 North Waukegan Road, North Chicago, Illinois 60064, U.S.A.

SOURCE AbbVie Inc.

The content and accuracy of news releases published on this site and/or distributed by PR Newswire or its partners are the sole responsibility of the originating company or organisation. Whilst every effort is made to ensure the accuracy of our services, such releases are not actively monitored or reviewed by PR Newswire or its partners and under no circumstances shall PR Newswire or its partners be liable for any loss or damage resulting from the use of such information. All information should be checked prior to publication.

-0- Mar/19/2013 07:56 GMT

Sponsored Links
Sponsored Links